^
    Back
    Association details:
    Biomarker:PIK3CA H1047R
    Cancer:Ovarian Cancer
    Drug:LX-086 (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO 2020
    Title:

    Preclinical evaluation of LX-086, a small molecule as a selective inhibitor of PI3K.

    Published date:
    05/28/2020
    Excerpt:
    LX-086 showed antitumor efficacy in HER2+/HR+, PIK3CA amplified breast cancer BT-474 CDX model (TGI = 106% @40 mpk, QD), as well as in the HER2-/HR+, PIK3CA H1047R breast cancer T47D CDX model (TGI = 84.7%@40 mpk, QD) and PIK3CA H1047R ovarian cancer SK-OV-3 CDX model (TGI = 69.2%@40 mpk, QD). 
    DOI:
    10.1200/JCO.2020.38.15_suppl.e15662